Substudy 06D: Combination Therapies in Second Line (2L) Gastroesophageal Adenocarcinoma (MK-3475-06D/Keymaker-U06)
NCT ID: NCT06445972
Last Updated: 2025-11-10
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
PHASE1/PHASE2
90 participants
INTERVENTIONAL
2024-08-07
2028-10-27
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Keywords
Explore important study keywords that can help with search, categorization, and topic discovery.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Sacituzumab Tirumotecan + Paclitaxel
Following a 28-day run-in with sacituzumab tirumotecan at 3 mg/kg and 4 mg/kg IV infusion on Days 1 and 15 of a 6-week cycle plus paclitaxel at 80 mg/M\^2 IV infusion on days 1, 8 and 15 of a 4-week cycle, participants will receive paclitaxel at 80 mg/M\^2 IV infusion on days 1, 8, 15 of each 4-week cycle (3 weeks on and 1 week off) up to \~60 weeks plus sacituzumab tirumotecan at selected dose IV infusion on days 1, 15, 29 of every 6-week cycle until discontinuation.
Paclitaxel
80 mg/M\^2 IV infusion
Sacituzumab Tirumotecan
3 mg/kg or 4 mg/kg IV Infusion
Rescue Medications
Participants receive rescue medications according to each approved drug's product label. Recommended rescue medications include antihistamines (histamine-1 and histamine-2 receptor antagonists), acetaminophen or equivalent, dexamethasone or equivalent infusion, and steroid mouth wash (dexamethasone or equivalent).
Ramucirumab + Paclitaxel
Participants will receive ramucirumab at 8mg/kg via intravenous (IV) infusion on days 1 and 15 of each 4-week cycle for up to \~60 weeks plus paclitaxel at 80 mg/M\^2 via IV infusion on Days 1, 8, and 15 of each 4-week cycle (3 weeks on and 1 week off) for up to \~60 weeks.
Ramucirumab
8 mg/kg IV Infusion
Paclitaxel
80 mg/M\^2 IV infusion
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Ramucirumab
8 mg/kg IV Infusion
Paclitaxel
80 mg/M\^2 IV infusion
Sacituzumab Tirumotecan
3 mg/kg or 4 mg/kg IV Infusion
Rescue Medications
Participants receive rescue medications according to each approved drug's product label. Recommended rescue medications include antihistamines (histamine-1 and histamine-2 receptor antagonists), acetaminophen or equivalent, dexamethasone or equivalent infusion, and steroid mouth wash (dexamethasone or equivalent).
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Has metastatic disease or locally advanced, unresectable disease
* Has experienced documented objective radiographic or clinical disease progression during or after 1L therapy containing any platinum/fluoropyrimidine doublet with or without immunotherapy
* Participants with gastroesophageal adenocarcinoma that is known to be human epidermal growth factor receptor 2 (HER2)/neu positive are excluded. Participants with unknown HER2 status are eligible.
* Has provided an archival tumor tissue sample or most recently obtained core, incisional, or excisional biopsy of a tumor lesion
* AEs due to previous anticancer therapies must be ≤Grade 1 or baseline (except alopecia and vitiligo). Endocrine-related AEs adequately treated with hormone replacement are acceptable.
* Has Eastern Cooperative Oncology Group performance status of 0 or 1
* Has a life expectancy of at least 3 months
* Participants who are hepatitis B surface antigen (HBsAg) positive are eligible if they have received Hepatitis B Virus (HBV) antiviral therapy for at least 4 weeks, and have undetectable HBV viral load prior to randomization.
* Participants with history of Hepatitis C Virus (HCV) infection are eligible if HCV viral load is undetectable at screening.
* Human Immunodeficiency Virus (HIV)-infected participants must have well controlled HIV on antiretroviral therapy.
Exclusion Criteria
* Has experienced weight loss \>20% over 3 months before the first dose of study intervention
* Has history of documented severe dry eye syndrome, severe Meibomian gland disease and/or blepharitis, or severe corneal disease that prevents/delays corneal healing
* Has Grade ≥2 peripheral neuropathy
* Has active inflammatory bowel disease requiring immunosuppressive medication or previous history of inflammatory bowel disease
* Has a serious or nonhealing wound or peptic ulcer or bone fracture within 28 days prior to randomization
* Has a bowel obstruction, history or presence of inflammatory enteropathy or extensive intestinal resection (hemicolectomy or extensive small intestine resection with chronic diarrhea)
* Has uncontrolled, significant cardiovascular disease or cerebrovascular disease
* Has experienced any arterial thrombotic event, including myocardial infarction, unstable angina, cerebrovascular accident, or transient ischemic attack, within 6 months prior to randomization
* Has uncontrolled arterial hypertension ≥150/≥90 mm mercury (Hg)
* Has accumulation of pleural, ascitic, or pericardial fluid requiring drainage or diuretic drugs within 2 weeks prior to enrollment
* Has undergone major surgery within 28 days prior to randomization, or central venous access device placement within 7 days prior to randomization or planned major surgery following initiation of study treatment
* Is receiving therapeutic anticoagulation with warfarin, low-molecular weight heparin or similar agents
* Is receiving chronic therapy with nonsteroidal anti-inflammatory agents (NSAIDs) or other antiplatelet agents
* Has a history of deep vein thrombosis, pulmonary embolism, or any other significant thromboembolism (venous port or catheter thrombosis or superficial venous thrombosis are not considered "significant") during the 3 months prior to randomization
* Has significant bleeding disorders, vasculitis, or had a significant bleeding episode from the gastrointestinal (GI) tract within 3 months prior to study entry
* Has history of GI perforation and/or fistulae within 6 months prior to randomization
* HIV-infected participants with a history of Kaposi's sarcoma and/or Multicentric Castleman's Disease
* Has received prior treatment with a trophoblast cell-surface antigen 2 (TROP2)-targeted antibody-drug conjugate (ADC), topoisomerase 1 inhibitor-based ADC and/or a topoisomerase 1 inhibitor-based chemotherapy
* Has received any previous systemic therapy targeting vascular endothelial growth factor (VEGF) or the vascular endothelial growth factor receptor (VEGFR) signaling pathways
* Has received prior systemic anticancer therapy including investigational agents within 4 weeks before the first dose of study drug intervention
* Has received prior radiotherapy within 2 weeks of start of study intervention, or has radiation-related toxicities, requiring corticosteroids
* Has received a live or live-attenuated vaccine within 30 days before the first dose of study intervention. Administration of killed vaccines is allowed
* Has received an investigational agent or has used an investigational device within 4 weeks prior to study intervention administration
* Has a known additional malignancy that is progressing or has required active treatment within the past 3 years. Basal cell carcinoma of the skin, squamous cell carcinoma of the skin, or carcinoma in situ, excluding carcinoma in situ of the bladder, that have undergone potentially curative therapy are not excluded.
* Has known active central nervous system (CNS) metastases and/or carcinomatous meningitis
* Has an active infection requiring systemic therapy
* Has a concurrent active HBV (defined as HBsAg positive and/or detectable HBV deoxyribonucleic acid) and HCV (defined as anti-HCV antibody positive and detectable HCV ribonucleic acid) infection
* History of (noninfectious) pneumonitis/interstitial lung disease that required steroids or has current pneumonitis/interstitial lung disease
* Has severe hypersensitivity (Grade ≥3) to sacituzumab tirumotecan, any of its excipients and/or to another biologic therapy
* Has not adequately recovered from major surgery or have ongoing surgical complications
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Merck Sharp & Dohme LLC
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Medical Director
Role: STUDY_DIRECTOR
Merck Sharp & Dohme LLC
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
University of Arizona Cancer Center-University of Arizona Cancer Center ( Site 8927)
Tucson, Arizona, United States
UCLA Hematology/Oncology - Santa Monica ( Site 8905)
Los Angeles, California, United States
Norton Cancer Institute - Downtown ( Site 8900)
Louisville, Kentucky, United States
The Cancer and Hematology Centers ( Site 8912)
Grand Rapids, Michigan, United States
Hematology-Oncology Associates of Central NY, P.C. ( Site 8925)
East Syracuse, New York, United States
Columbia University Irving Medical Center-CUIMC Herbert Irving Comprehensive Cancer Center Clinical ( Site 8907)
New York, New York, United States
UPMC Hillman Cancer Center-UPMC ( Site 8904)
Pittsburgh, Pennsylvania, United States
University of Texas MD Anderson Cancer Center ( Site 8920)
Houston, Texas, United States
Liga Norte Riograndense Contra o Câncer ( Site 8303)
Natal, Rio Grande do Norte, Brazil
Hospital Nossa Senhora da Conceição ( Site 8301)
Porto Alegre, Rio Grande do Sul, Brazil
IBCC - Instituto Brasileiro de Controle do Câncer ( Site 8304)
São Paulo, São Paulo, Brazil
Clínica Puerto Montt ( Site 8409)
Port Montt, Los Lagos Region, Chile
Centro de Investigación del Maule ( Site 8408)
Talca, Maule Region, Chile
FALP-UIDO ( Site 8400)
Santiago, Region M. de Santiago, Chile
Centro de Oncología de Precisión-Oncology ( Site 8404)
Santiago, Region M. de Santiago, Chile
Clínica UC San Carlos de Apoquindo ( Site 8405)
Santiago, Region M. de Santiago, Chile
Bradfordhill-Clinical Area ( Site 8401)
Santiago, Region M. de Santiago, Chile
Bradford Hill Norte ( Site 8407)
Antofagasta, , Chile
Beijing Cancer hospital-Digestive Oncology ( Site 7500)
Beijing, Beijing Municipality, China
The 900th Hospital of the Joint Logistics Support Force of the Chinese People's Liberation Army ( Site 7501)
Fuzhou, Fujian, China
The First Affiliated hospital of Xiamen University ( Site 7503)
Xiamen, Fujian, China
Henan Cancer Hospital ( Site 7504)
Zhengzhou, Henan, China
The First Affiliated Hospital of Nanchang University ( Site 7514)
Nanchang, Jiangxi, China
Fudan University Shanghai Cancer Center ( Site 7513)
Shanghai, Shanghai Municipality, China
Xinjiang Medical University Cancer Hospital - Urumqi ( Site 7506)
Ürümqi, Xinjiang, China
Sir Run Run Shaw Hospital of Zhejiang University School of Medicine ( Site 7510)
Hangzhou, Zhejiang, China
Centre Hospitalier Régional Universitaire de Brest - Hôpital-Institut de cancérologie et hématologi ( Site 7104)
Brest, Finistere, France
CIC. ( Site 7100)
Lille, Nord, France
Pitie Salpetriere University Hospital-Hepato-Gastro-Enterology ( Site 7102)
Paris, Île-de-France Region, France
Universitaetsklinikum Duesseldorf-Gastroenterology, Hepatology and Infectiology ( Site 8802)
Düsseldorf, North Rhine-Westphalia, Germany
Facharztzentrum Eppendorf-Facharztzentrum Eppendorf ( Site 8807)
Hamburg, , Germany
IRCCS - Istituto Romagnolo per lo Studio dei Tumori (IRST) "Dino Amadori"-Oncologia Medica ( Site 7207)
Meldola, Emilia-Romagna, Italy
Fondazione IRCCS Istituto Nazionale dei Tumori-Struttura Complessa Oncologia Medica 1 ( Site 7200)
Milan, Lombardy, Italy
Oslo universitetssykehus, Radiumhospitalet ( Site 8501)
Oslo, , Norway
Asan Medical Center-Department of Oncology ( Site 7901)
Seoul, , South Korea
Samsung Medical Center-Division of Hematology/Oncology ( Site 7900)
Seoul, , South Korea
Hôpitaux Universitaires de Genève (HUG) ( Site 8701)
Geneva, Canton of Geneva, Switzerland
Kantonsspital Graubünden-Medizin ( Site 8700)
Chur, Kanton Graubünden, Switzerland
China Medical University Hospital ( Site 8007)
Taichung, , Taiwan
National Cheng Kung University Hospital ( Site 8001)
Tainan, , Taiwan
National Taiwan University Hospital-Oncology ( Site 8000)
Taipei, , Taiwan
Taipei Veterans General Hospital ( Site 8005)
Taipei, , Taiwan
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Related Links
Access external resources that provide additional context or updates about the study.
Merck Clinical Trials Information
Plain Language Summary
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2023-509306-29-00
Identifier Type: REGISTRY
Identifier Source: secondary_id
U1111-1299-8160
Identifier Type: REGISTRY
Identifier Source: secondary_id
MK-3475-06D
Identifier Type: OTHER
Identifier Source: secondary_id
3475-06D
Identifier Type: -
Identifier Source: org_study_id